444143-17-3

Basic information

• Product Name: 4-(2-FLUORO-3-TRIFLUOROMETHYL-PHENYL)-THIAZOL-2-YLAMINE
• Synonyms: 4-(2-FLUORO-3-TRIFLUOROMETHYL-PHENYL)-THIAZOL-2-YLAMINE
• CAS NO: 444143-17-3
• Molecular Formula: C₁₀H₆F₄N₂S
• Molecular Weight: 262.23
• Mol File: 444143-17-3.mol

Chemical Properties

• Boiling Point: 359.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.478±0.06 g/cm3(Predicted)
• PKA: 3.24±0.10(Predicted)
• CAS DataBase Reference: 4-(2-FLUORO-3-TRIFLUOROMETHYL-PHENYL)-THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-FLUORO-3-TRIFLUOROMETHYL-PHENYL)-THIAZOL-2-YLAMINE(444143-17-3)
• EPA Substance Registry System: 4-(2-FLUORO-3-TRIFLUOROMETHYL-PHENYL)-THIAZOL-2-YLAMINE(444143-17-3)

Safety Data

• Hazardous Substances Data: 444143-17-3(Hazardous Substances Data)

Usage

Chemical Structure

Thiazole derivative with fluorine and trifluoromethyl substituents on the phenyl ring

Usage

Pharmaceutical industry, particularly in drug development

Biological Properties

Potential enzyme inhibitor, studied for anti-inflammatory and anti-cancer properties

Research Significance

Target for further research and development in medicinal chemistry

Upstream product

• 207853-63-2 2'-fluoro-3'-trifluoromethylacetophenone 
• 17356-08-0 thiourea 

Downstream Products

• 881400-37-9 4-(6-Chloro-pyrimidin-4-ylamino)-N-[4-(2-fluoro-3-trifluoromethyl-phenyl)-thiazol-2-yl]-benzamide 
• 881402-05-7 N-(4-(2-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-yl)-4-iodobenzene 
• 1201825-53-7 N-(chloro(methyl)alumino)-4-(2-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-amine 

Relevant articles and documents

PYRIDO[3,4-D]PYRIMIDINYL ACETAMIDE DERIVATIVES AS TRPA1 MODULATORS

Provided are pyrido[3,4-d]pyrimidinyl acetamide derivatives as Transient Receptor Potential Ankyrin (TRPA) modulators. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Transient Receptor Potential Ankyrin 1 (TRPAl). Also provided herein are processes for preparing the compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. Formula (I).

FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS

The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl. Formula (I)

PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS

The present invention is related to novel pyrimidinedione-fused heterocyclic compounds as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

Thrombopoietin Receptor Agonists

A compound of the formula (I) useful as promoters of thrombopoiesis and megakaryocytopoiesis, wherein A, B, D, E, W, X, Y, Z, R1 and R2 are defined as above.

AMINOTHIAZOLE DERIVATIVES AS AGONISTS OF THE THROMBOPOIETIN RECEPTOR

A compound of the formula (I) wherein R1, R2, R3, X, and d are defined as above. The presently disclosed compounds are TPO agonists useful as promoters of thrombopoiesis and megakaryocytopoiesis.

HALOGEN COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM

Compounds of the general formula (III), prodrugs thereof, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: wherein R9 is hydrogen atom, optionally substituted lower alkyl, or the lik